A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Genmab A/S stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 14,803 shares of GMAB stock, worth $410,783. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,803
Previous 19,906 25.64%
Holding current value
$410,783
Previous $633,000 30.17%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 01, 2024

SELL
$26.43 - $32.77 $134,872 - $167,225
-5,103 Reduced 25.64%
14,803 $442,000
Q4 2023

Jan 24, 2024

BUY
$27.94 - $35.44 $1,732 - $2,197
62 Added 0.31%
19,906 $633,000
Q3 2023

Oct 26, 2023

SELL
$35.27 - $42.24 $70,081 - $83,930
-1,987 Reduced 9.1%
19,844 $699,000
Q2 2023

Aug 10, 2023

SELL
$37.4 - $42.94 $76,258 - $87,554
-2,039 Reduced 8.54%
21,831 $829,000
Q1 2023

May 04, 2023

SELL
$34.88 - $43.22 $762,128 - $944,357
-21,850 Reduced 47.79%
23,870 $901,000
Q4 2022

Feb 09, 2023

SELL
$33.8 - $47.06 $400,462 - $557,566
-11,848 Reduced 20.58%
45,720 $1.94 Million
Q3 2022

Nov 10, 2022

SELL
$31.52 - $373.61 $1.79 Million - $21.2 Million
-56,764 Reduced 49.65%
57,568 $1.84 Million
Q2 2022

Jul 26, 2022

BUY
$26.83 - $38.57 $1.59 Million - $2.29 Million
59,300 Added 107.76%
114,332 $2.58 Million
Q1 2022

May 10, 2022

SELL
$30.95 - $39.68 $18,786 - $24,085
-607 Reduced 1.09%
55,032 $1.99 Million
Q4 2021

Feb 08, 2022

SELL
$35.87 - $47.12 $2,188 - $2,874
-61 Reduced 0.11%
55,639 $2.21 Million
Q3 2021

Nov 15, 2021

BUY
$41.55 - $48.72 $238,330 - $279,457
5,736 Added 11.48%
55,700 $2.43 Million
Q2 2021

Aug 11, 2021

SELL
$32.88 - $44.57 $335,573 - $454,881
-10,206 Reduced 16.96%
49,964 $2.04 Million
Q1 2021

May 13, 2021

BUY
$30.92 - $44.4 $528,144 - $758,396
17,081 Added 39.64%
60,170 $1.98 Million
Q4 2020

Feb 10, 2021

BUY
$33.66 - $40.76 $1.45 Million - $1.76 Million
43,089 New
43,089 $1.75 Million

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $18.3B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Mirae Asset Global Investments Co., Ltd. Portfolio

Follow Mirae Asset Global Investments Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.